In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amgen licenses Immunomedics' cancer antibody; terminated

Executive Summary

Amgen has licensed from Immunomedics (cancer and infectious disease diagnostics and therapeutics) a humanized monoclonal antibody, LymphoCide (epratuzumab), in Phase III to treat non-Hodgkin's lymphoma. It will pay (uf)$18mm up front, up to $65mm in clinical milestones, and one-time sales milestones of $50-225mm if net sales reach between $500mm to $1bn.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies